학술논문

Current and Future Treatments in Primary Ciliary Dyskinesia.
Document Type
Article
Source
International Journal of Molecular Sciences. Sep2021, Vol. 22 Issue 18, p9834. 1p.
Subject
*MUCOCILIARY system
*CILIARY motility disorders
*LUNGS
*DISEASE relapse
*CYSTIC fibrosis
*RESPIRATORY insufficiency
*GENE therapy
Language
ISSN
1661-6596
Abstract
Primary ciliary dyskinesia (PCD) is a rare genetic ciliopathy in which mucociliary clearance is disturbed by the abnormal motion of cilia or there is a severe reduction in the generation of multiple motile cilia. Lung damage ensues due to recurrent airway infections, sometimes even resulting in respiratory failure. So far, no causative treatment is available and treatment efforts are primarily aimed at improving mucociliary clearance and early treatment of bacterial airway infections. Treatment guidelines are largely based on cystic fibrosis (CF) guidelines, as few studies have been performed on PCD. In this review, we give a detailed overview of the clinical studies performed investigating PCD to date, including three trials and several case reports. In addition, we explore precision medicine approaches in PCD, including gene therapy, mRNA transcript and read-through therapy. [ABSTRACT FROM AUTHOR]